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Pituitary adenoma is a common disease occurring in pituitary that is a central regulatory organ in 
endocrine system and is clinically categorized as functional and non-functional pituitary adeno-
mas (FPA and NFPA) (1–4). FPA commonly includes adrenocorticotropic hormone (ACTH)-cell 
adenoma, thyrotropin-stimulating hormone (TSH)-cell adenoma, growth hormone (GH)-cell 
adenoma, and prolactin (PRL)-cell adenoma (5). Compared to FPA, NFPA is a very challenging 
clinical problem due to no any increase of corresponding serum hormone, which results in difficulty 
in early-stage diagnosis and therapy of an NFPA (1, 2). Moreover, high-degree heterogeneity occurs 
in NFPAs, which is present as different subtypes of cell origins and hormones expressed in a tumor 
tissue; for example, intact gonadotroph with luteinizing hormone (LH)/follicle-stimulating hormone 
(FSH)-positive (40–79%), null cell without hormone expression (17%), oncocytoma without hor-
mone expression (6%), silent corticotroph with ACTH-positive (8%), and silent somatotroph with 
GH-positive (3%). The intact gonadotroph is subdivided into LH+, FSH+, and LH/FSH+ positive 
NFPAs (5, 6). The very interesting thing is that the silent hormone expressed in an NFPA tissue 
associates tumor biological behaviors, such as invasive characteristics (7, 8); for example, a clinically 
silent corticotroph tumor of a pituitary shows symptomatic cystic degeneration (7), and estrogen 
receptors and slug contribute to development of invasiveness of an NFPA (8). In addition, NFPA 
is a very complex whole-body disease with multiple molecule dynamic alterations in the levels of 
genome, transcriptome, proteome, and metabolome, and those different levels of multiple molecules 
constitute three-dimensional spatial interactome to exert their biological roles in an NFPA biological 
system from an angle of multiparameter systematic strategy (9–12). The documented omics data 
demonstrate obvious variations in transcriptome and proteome between NFPAs and controls (6), 
between invasive and non-invasive NFPAs (13, 14), and among four hormone-expressed NFPA 
subtypes (1). Also, post-transcriptional splicing and numerous post-translational modifications 
(PTMs) contribute to the complexities of transcriptome and proteome and cause the interactome 
more complex and more dynamic (15); for example, the literature demonstrates the splicing vari-
ants/isoforms of hormones, such as GH and prolactin, and PTMs, such as tyrosine nitration and 
phosphorylation that occur in NFPAs (6, 16, 17). One should understand the interactome in three 
levels including alterations in single molecule, molecule profile, and molecular network profile in an 
NFPA. Molecular network is the carrier to recognize the interactome from a view point of systematic 
strategy. More attentions have been paid to molecular network of NFPA because it changes the 
single-one parameter model to multiparameter systematic strategy model, which meets the reality 
of complicated pathophysiological processes of an NFPA (9–11). Therefore, recognition of molecular 
network variations would benefit clarification of molecular mechanisms and discovery of reliable 
biomarkers and therapeutic targets of an NFPA toward personalized medicine (18) and precision 
medicine (19) practices.
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In our studies on NFPA, two-dimensional gel electrophoresis 
(2DGE)-based quantitative proteomics, PTM-proteomics, bioin-
formatics, and pathway network-based systems biology were used 
to investigate the variations in proteome and protein molecular 
networks of an NFPA (1, 6, 14, 16, 20). (i) For NFPAs compared 
to pituitary controls (6, 16, 20), a set of 50 differentially expressed 
proteins (DEPs), 9 nitroproteins, and 3 nitroprotein–protein 
complexes were identified (6, 16). Pathway network analysis 
revealed four important pathway network systems that operate 
in an NFPA, including mitochondrial dysfunction, oxidative 
stress, cell-cycle dysregulation, and MAPK-signaling abnormal-
ity (20). (ii) For invasive relative to non-invasive NFPAs (14), a 
set of 57 DEPs were identified. Pathway network analysis revealed 
eight important pathway networks that associate the invasive 
characteristics of invasive NFPAs, including mitochondrial dys-
function, oxidative stress, MAPK-signaling abnormality, prote-
olysis abnormality, CDK5 signaling abnormality, ketogenesis and 
ketolysis, TR/RXR activation, and amyloid processing. (iii) For 
comparison of four hormone-expressed subtypes of NFPAs (NF−, 
LH+, FSH+, and LH/FSH+; NF− means NFPA that had negative 
immunohistochemical stains for ACTH, FSH, GH, LH, prolactin, 
and TSH) versus pituitary controls (Con) (1), a total of 76 DEPs 
was identified, including 59 DEPs in NF vs. Con, 65 DEPs in 
LH vs. Con, 63 DEPs in FSH vs. Con, and 55 DEPs in LH/FSH 
vs. Con. Overlapping and pathway network analyses revealed a 
set of DEPs and pathway networks that are common and spe-
cific to each NFPA subtype; of them, four important common 
pathway systems were MAPK-signaling abnormality, oxidative 
stress, mitochondrial dysfunction, and cell-cycle dysregulation. 
However, those four common pathway network systems were 
significantly different among four NFPA subtypes with variations 
in three different aspects, including different protein expression 
levels of most of protein nodes, different protein profiles, and 
different pathway network profiles (1, 21). With comprehensive 
consideration of three sets of quantitative proteomics data-based 
pathway network analyses between (a) NFPAs versus controls, 
(b) invasive versus non-invasive NFPAs, and (c) four hormone-
expressed NFPA subtypes, some interesting results were found 
that (i) three pathway network systems including mitochondrial 
dysfunction, oxidative stress, and MAPK-signaling abnormality 
were identified from three sets of analyses (a)–(c), (ii) cell-cycle 
dysregulation was identified from two sets of analyses (a) and 
(c) but not (b), and (iii) the components (expression level of 
each protein node and protein profile) of each pathway network 
system were different among three sets of analyses (a)–(c). Those 
data clearly indicate the common and specific molecular network 
variations in NFPAs and among different subtypes of NFPAs.
Those data provide a preliminary view of molecular network 
variations in NFPAs and its subtypes. However, one should realize 
the limitations of those mentioned studies and the directions of 
further studies: (i) those molecular networks derived from 2DGE 
quantitative proteomics data were constructed with bioinformat-
ics and systems biology. The biological relevance of each molecular 
network in the pathophysiological processes of an NFPA should 
be further studied with in vitro and in vivo experiments. (ii) 2DGE 
quantitative proteomics has obvious limitations in maximizing 
the coverage of an NFPA proteome. The 2DGE with an 18-cm 
pH3-10 NL IPG strip and 12% SDS-PAGE isolation in mentioned 
studies detected proteins within a range of Mr 5–150 kDa and 
pH 4–8 (5, 22). Multi-dimensional liquid chromatography 
(MDLC) in combination with tandem mass spectrometry (MS/
MS) is needed to maximize the coverage of NFPA proteome for 
molecular network analysis (22). (iii) Protein variants/isoforms 
and PTMs are the important aspects in a proteome and associate 
many important physiological and pathological processes (15). 
Barely studies are found to explore globally and systematically 
protein variants/isoforms and PTMs in an NFPA and how those 
protein variants/isoforms and PTMs affect the molecular network 
systems in an NFPA, even though several PTMs, such as tyrosine 
nitration (16, 23) and phosphorylation (17, 24), and protein vari-
ants/isoforms such as GH isoforms and PRL isoforms (6, 25) were 
preliminarily investigated in NFPAs. (iv) Transcriptomics data 
between NFPAs and controls (6) and invasive and non-invasive 
NFPAs (13) have been documented. However, transcriptomics 
data-based molecular network analysis has not been systemati-
cally carried out in those studies (6, 13). An integrated molecular 
network based on omics data including genomic, transcriptomic, 
proteomic, peptidomic, and metabolomic data would have 
more important biological significance in the clarification of 
molecular mechanisms and discovery of reliable biomarkers for 
an NFPA patient (10). (v) NFPA is highly heterogeneous tumor. 
The documented molecular network variation studies between 
NFPAs versus controls (6, 20), invasive and non-invasive NFPAs 
(14), and four NFPA subtypes (NF−, LH+, FSH+, and LH/FSH+) 
subtypes (1) should be extended to other NFPA subtypes, such 
as silent ACTH- and GH-positive NFPAs, and different FPA 
subtypes, such as ACTH-, TSH-, GH-, and PRL-cell FPAs (5).
In summary, NFPA has high-degree heterogeneity and dif-
ficulty in its early-stage diagnosis and therapy. From the angle of 
systems biology strategy, exploration of variations in molecular 
networks that operate in an NFPA will be an important approach 
to the in-depth understanding of molecular mechanisms and dis-
cover effective and reliable biomarkers and therapeutic targets for 
personalized and precision medicine practices in an NFPA patient.
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